首页 Mirati Therapeutics(usMRTX)-基本信息

Mirati Therapeutics(usMRTX)-基本信息

日报更新时间:

周报更新时间:01-23 11:54

行情信息

今开价:211.4

最高价:214.75

成交量:322181.0

昨收价:212.93

最低价:211.15

最新价:214.45

行情图标
概要信息

英文名称:Mirati Therapeutics


简介:Mirati Therapeutics,Inc.于2013年4月29日根据特拉华州法律注册成立,是一家临床阶段的生物制药公司,致力于开发针对性的肿瘤产品管道


电话:1-858-3323410


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Mirati Therapeutics是一家临床阶段肿瘤学公司,在美国开发候选产品以解决癌症的遗传和免疫启动子问题。Mirati Therapeutics公司参与开发了一种光谱选择性激酶抑制剂Sitravatinib,该药物正处于治疗非小细胞肺癌(NCSLC)的 II 期临床阶段;以及用于治疗NCSLC患者Casitas B系淋巴瘤基因改变的 Ib 期临床试验;和用于NSCLC腺癌患者,结肠直肠癌患者和其他癌症的KRAS G12C抑制剂计划。Mirati Therapeutics还开发了mocetinostat,一种口服研究的选择性 I 类和 IV 类组蛋白去乙酰化酶抑制剂,已与Ourvalumab联合完成II期临床试验,用于治疗NSCLC。Mirati Therapeutics公司与BeiGene, Ltd.签订了合作和许可协议,以开发,生产和商业化sitravatinib。Mirati Therapeutics公司的临床阶段的候选产品包括: MGCD265,一种多标靶的激酶抑制剂,目前处于Ib临床开发试验阶段,用于治疗非小细胞肺癌和其他实体肿瘤,例如在胃中发现的癌症的和头颈部的鳞状细胞癌; MGCD516,一种激酶抑制剂,目前处于Ib临床开发阶段,用于治疗具有重视基因改变的实体肿瘤。 Mocetinostat,一种口服生物可利用的组蛋白脱乙酰酶抑制剂,目前处于II期临床试验阶段,用于膀胱癌、骨髓增生异常综合征和非霍奇金淋巴瘤患者,主要是弥漫性大B细胞淋巴瘤和滤泡性淋巴瘤。Mirati Therapeutics公司与Foundation Medicine, Inc.和Guardant Health, Inc.达成合作协议一起探索他们为了MGCD265作为伴随性诊断平台的开发和QIAGEN NV有合作伙伴关系,开发和商业化一项伴随性诊断测试来指导glesatinib (MGCD265)的使用,与一项用于非小细胞肺癌的标靶治疗正在开发。

交易日期 交易人 职位 类型 交易份额 价格
2017-01-25 Braslyn Ltd. Beneficial Owner of More than 10% Class Buy 28839 5.45
2017-01-25 Braslyn Ltd. Beneficial Owner of More than 10% Class Buy 19330 5.44
2017-01-24 Braslyn Ltd. Beneficial Owner of More than 10% Class Buy 30600 5.42
2017-01-23 Braslyn Ltd. Beneficial Owner of More than 10% Class Buy 27682 5.32
2017-01-22 Braslyn Ltd. Beneficial Owner of More than 10% Class Buy 19251 5.27
2017-01-19 Braslyn Ltd. Beneficial Owner of More than 10% Class Buy 23873 5.42
2017-01-18 Braslyn Ltd. Beneficial Owner of More than 10% Class Buy 21085 5.48
2017-01-17 Braslyn Ltd. Beneficial Owner of More than 10% Class Buy 16200 5.50
2017-01-16 Braslyn Ltd. Beneficial Owner of More than 10% Class Buy 17800 5.50
2017-01-12 Braslyn Ltd. Beneficial Owner of More than 10% Class Buy 52311 5.49
2017-01-11 Braslyn Ltd. Beneficial Owner of More than 10% Class Buy 49776 5.50
2017-01-05 Braslyn Ltd. Beneficial Owner of More than 10% Class Buy 581870 5.60
2017-01-05 Boxer Capital L L C Beneficial Owner of More than 10% Class Buy 280059 5.60
2017-01-05 Boxer Capital L L C Beneficial Owner of More than 10% Class Buy 6104 5.60
2016-06-13 Baum (Charles M) Chief Executive Officer Buy 20000 7.05
2016-06-08 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Sell 2318 9.56
2016-06-08 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Sell 158684 9.56
2016-06-08 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Sell 9056 9.56
2016-06-08 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Sell 19970 9.40
2016-06-08 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Sell 349919 9.40
2016-06-08 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Sell 5111 9.40
2016-06-07 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Sell 147529 9.21
2016-06-07 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Sell 2154 9.21
2016-06-07 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Sell 8417 9.21
2016-06-06 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Sell 275506 9.44
2016-06-06 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Sell 16493 9.44
2016-06-06 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Sell 16493 9.44
2016-06-06 BAKER BROS ADVISORS L P Beneficial Owner of More than 10% Class Sell 4201 9.44
2016-06-05 Braslyn Ltd. Beneficial Owner of More than 10% Class Buy 215151 10.31
2016-05-05 Braslyn Ltd. Beneficial Owner of More than 10% Class Buy 4500 17.15
第 页, 共 2 页 首页 上页 下页 末页

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Fidelity SelectCo, LLC 900044 2.29% -179216 -16.61% 2019-07-31
HHG PLC 2034744 5.64% 956022 88.63% 2019-03-31
Vanguard Group Inc 2182038 6.05% 750022 52.38% 2019-03-31
BlackRock Inc 2336095 6.48% 283146 13.79% 2019-03-31
Baker Bros Advisors LP 2513462 6.97% -- -- 2019-03-31
Aviva Holdings Ltd 3135966 8.70% -- -- 2019-03-31
venBio Select Advisor LLC 3862500 10.72% -935601 -19.50% 2019-03-31
Fidelity Management and Research Company 4021270 11.16% 1861582 86.20% 2019-03-31
FMR Inc 4606270 12.78% 2409882 109.72% 2019-03-31
Fidelity Management & Research Company 1900374 4.84% -601850 -24.05% 2019-07-31
Boxer Capital LLC 1715560 4.76% 150000 9.58% 2019-03-31
State Street Corporation 1412039 3.92% -119510 -7.80% 2019-03-31
Vanguard Investments Australia Ltd 900767 2.29% 35121 4.06% 2019-07-31
Janus Capital Management LLC 992144 2.52% -146392 -12.86% 2019-07-31
EcoR1 Capital, LLC 1000000 2.77% 352831 54.52% 2019-03-31
Cormorant Asset Management, LLC 1075000 2.98% -676699 -38.63% 2019-03-31
BlackRock Fund Advisors 1178915 3.00% -46891 -3.83% 2019-07-31
Perceptive Advisors LLC 1164382 3.23% 1038507 825.03% 2019-03-31
Jennison Associates LLC 1192679 3.31% -23785 -1.96% 2019-03-31
Farallon Capital Management, L.L.C. 1200000 3.33% -100000 -7.69% 2019-03-31
SSGA Funds Management Inc 975269 2.71% -888 -0.09% 2019-05-31
Deerfield Management Co 874486 2.43% 33575 3.99% 2018-12-31
OppenheimerFunds Inc 816810 2.32% 291544 55.50% 2018-12-31
Bvf Inc 723322 2.22% -21678 -2.91% 2018-09-30
PGIM Investments LLC 666623 2.05% 966 0.15% 2018-12-31
BlackRock Institutional Trust Company NA 707717 2.18% 253725 55.89% 2018-06-30
Broadfin Capital, LLC 1020178 3.14% -423770 -29.35% 2018-06-30
Putnam Investment Management, LLC 685225 2.11% -212095 -23.64% 2018-10-31
State Street Corp 975822 3.02% 278115 39.86% 2018-06-30
Marshall Wace North America LP 804776 2.49% 495017 159.81% 2018-06-30
Ghost Tree Capital, LLC 500000 1.55% 237500 90.48% 2018-06-30
Driehaus Capital Management LLC 441470 1.37% 441470 -- 2018-06-30
Dimensional Fund Advisors, Inc. 314306 0.97% -20261 -6.06% 2018-06-30
Invesco PowerShares Capital Mgmt LLC 251986 0.72% 790 0.31% 2018-08-30
Geode Capital Management, LLC 271743 0.84% 87337 47.36% 2018-06-30
Putnam Investment Management,LLC 693567 2.39% -246041 -26.19% 2018-03-31
Janus Capital International Ltd 170538 0.53% 170538 -- 2018-06-30
D. E. Shaw & Co LP 284091 0.98% -194392 -40.63% 2018-03-31
Millennium Management LLC 381924 1.32% 381924 -- 2018-03-31
Point72 Asset Management, L.P. 407929 1.41% 327030 404.24% 2018-03-31
OFI Global Asset Management, Inc. 348880 1.08% 348880 -- 2018-06-30
Delaware Management Business Trust 223630 0.77% 143630 179.54% 2018-03-31
Prudential Investments LLC 256805 0.88% -- -- 2018-05-31
Rock Springs Capital Management LP 189000 0.65% 9000 5.00% 2018-03-31
Longwood Capital Partners LLC 155000 0.54% 155000 -- 2017-12-31
Bogle Investment Management L P 137671 0.48% 137671 -- 2017-12-31
Royce & Associates, LLC 121100 0.42% -130000 -51.77% 2017-12-31
Deutsche Asset & Wealth Management Investment GmbH 80273 0.28% 80273 -- 2018-01-31
Morgan Stanley & Co Inc 151319 0.61% 150151 12855.39% 2017-09-30
Delaware Management Company 215937 0.85% 135937 169.92% 2018-01-31
Macquarie Investment Management Limited 80000 0.32% 80000 -- 2017-09-30
PDT Partners, LLC 68200 0.27% 13500 24.68% 2017-09-30
SIMPLEX TRADING, LLC 77903 0.31% 77580 24018.58% 2017-09-30
Baker Bros Advisors Llc 2549598 10.08% 280400 12.36% 2017-11-16
JANE STREET GROUP, LLC 57127 0.23% 57127 -- 2017-09-30
Northern Trust Investments N A 53401 0.21% 9036 20.37% 2017-09-30
Virtus ETF Advisers LLC 19786 0.09% -- -- 2017-12-28
Goldman, Sachs & Co. 98251 0.39% 87858 845.36% 2017-06-30
Oxford Asset Management, LLC 32181 0.12% 32181 -- 2017-09-30
Element Capital Management LLC 107222 0.43% 107222 -- 2017-06-30
Sabby Management LLC 255100 1.01% 5365 2.15% 2017-06-30
Franklin Advisers Inc 613996 3.08% -- -- 2016-09-30
Great Point Partners LLC 227657 1.14% 227657 -- 2016-09-30
Sphera Funds Management Ltd. 150000 0.75% -- -- 2016-09-30
RTW INVESTMENTS, LLC 129129 0.65% -1923 -1.47% 2016-09-30
Renaissance Technologies Corp 106800 0.54% -128920 -54.69% 2016-09-30
Deutsche Bank AG 91952 0.46% -8234 -8.22% 2016-09-30
TIAA-CREF Investment Management LLC 79147 0.40% 28775 57.12% 2016-09-30
Franklin Advisers, Inc. 842346 2.00% 19079137 0.10% 1999-11-30
OrbiMed Private Investments IV,LP 1267000 2.00% 28697550 0.10% 1999-11-30
FMR LLC 2172603 2.00% 49209458 0.20% 1999-11-30
Baker Bros. Advisors, LLC 2805074 2.00% 63534926 0.20% 1999-11-30
Tavistock Life Sciences, LLC 2930072 2.00% 66366131 0.20% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Vanguard Small Cap Value Index Fund 514595 1.31% 135885 35.88% 2019-06-30
Vanguard Total Stock Market Index Fund 895509 2.28% 35151 4.09% 2019-06-30
Vanguard Small Cap Index 829334 2.11% 235229 39.59% 2019-06-30
SPDR 596738 1.52% 9270 1.58% 2019-07-31
iShares Russell 2000 ETF 549596 1.40% 5550 1.02% 2019-07-30
iShares Russell 2000 Growth ETF 229159 0.58% 2712 1.20% 2019-07-30
Vanguard Extended Market Index Fund 481197 1.22% 5214 1.10% 2019-06-30
T. Rowe Price Health Sciences Fund 440926 1.12% 120800 37.74% 2019-06-30
Invesco Oppenheimer Global Fund 440646 1.12% -- -- 2019-06-30
Fidelity 251836 0.64% -534 -0.21% 2019-04-30
Janus Henderson Global Life Sciences Fd 258805 0.66% -1993 -0.76% 2019-06-30
PGIM Jennison Health Sciences Fund 339643 0.86% -- -- 2019-06-30
iShares Nasdaq Biotechnology ETF 355840 0.91% 3628 1.03% 2019-07-30
T. Rowe Price New Horizons Fund 370507 0.94% 129700 53.86% 2019-06-30
Janus Henderson Research Fund 396367 1.01% -- -- 2019-06-30
Fidelity Advisor 239020 0.66% -45800 -16.08% 2019-05-31
PGIM Jennison Small Company Fund 246555 0.68% -- -- 2019-05-31
Franklin Biotechnology Discovery Fund 248500 0.69% -- -- 2019-05-31
iShares US Small Cap ETF (CAD-Hedged) 438643 1.22% -738 -0.17% 2019-05-30
Vanguard Small Cap Index Fund 402460 1.12% 4322 1.09% 2019-04-30
Oppenheimer Global Fund 440646 1.22% -- -- 2019-03-31
Putnam Global Health Care Fund 345911 0.96% 345911 -- 2018-12-31
Lord Abbett Developing Growth Fund 210558 0.60% -- -- 2019-02-28
Delaware Healthcare Fund 223630 0.63% -- -- 2019-02-28
Wells Fargo Discovery Fund 211400 0.60% -- -- 2019-01-31
Candriam Eqs L Biotechnology 211000 0.60% -- -- 2019-01-31
BlackRock Health Sciences Opps Port 214050 0.61% 138050 181.64% 2019-01-31
Janus Henderson Venture Fund 155127 0.48% 39635 34.32% 2018-12-31
Threadneedle American Smlr Coms Fd(US) 147951 0.46% 62944 74.05% 2018-10-31
Invesco DWA Healthcare Momentum ETF 139257 0.43% -- -- 2018-11-30
Oppenheimer Global Fund/VA 99073 0.30% 34579 53.62% 2018-10-31
Prudential Jennison Health Sciences A 316359 0.98% -- -- 2018-07-31
Oppenheimer Global A 277633 0.86% -- -- 2018-07-31
Janus Global Life Sciences D 297055 0.92% 297055 -- 2018-06-30
Delaware Healthcare A 223630 0.69% -- -- 2018-07-31
iShares Russell 2000 Growth 172862 0.52% -167 -0.10% 2018-09-12
Wells Fargo Discovery Admin 150300 0.46% 150300 -- 2018-07-31
Fidelity Spartan 142697 0.44% -- -- 2018-07-31
PowerShares DWA Healthcare Momentum ETF 150579 0.46% -- -- 2018-09-13
PowerShares DWA SmallCap Momentum ETF 123259 0.37% -- -- 2018-09-13
DFA US Micro Cap I 78391 0.24% -- -- 2018-07-31
Oppenheimer Global VA Svc 64494 0.20% -1028 -1.57% 2018-07-31
Vanguard Extended Market Idx Inv 420800 1.30% 4500 1.08% 2018-07-31
Vanguard Total Stock Mkt Idx 714101 2.21% -- -- 2018-07-31
Driehaus Micro Cap Growth 103965 0.32% -10022 -8.79% 2018-07-31
Vanguard Explorer Inv 70546 0.22% 70546 -- 2018-06-30
JNL/Oppenheimer Global Growth B 67194 0.21% 67194 -- 2018-06-30
Putnam Capital Opportunities A 123683 0.43% -60894 -32.99% 2018-03-31
Putnam Global Health Care A 459534 1.58% -167019 -26.66% 2018-03-31
iShares Micro-Cap 47502 0.18% -- -- 2018-07-26
ALPS Medical Breakthroughs ETF 44672 0.18% -- -- 2018-07-27
BlackRock Extended Equity Market K 49566 0.15% 7300 17.27% 2018-06-30
Royce Micro Cap Trust 61100 0.21% -60000 -49.55% 2018-03-31
Vanguard Health Care ETF 37875 0.13% 37875 -- 2018-05-31
BioShares 44105 0.16% -- -- 2018-06-14
Putnam VT Global Health Care IA 48500 0.17% -15734 -24.49% 2018-03-31
DFA US Small Cap I 38591 0.13% -- -- 2018-03-31
Vanguard Instl Ttl Stk Mkt Idx InstlPls 35713 0.12% -3287 -8.43% 2018-03-31
DFA US Targeted Value I 31656 0.11% -- -- 2018-02-28
DFA US Core Equity 2 I 33499 0.12% -- -- 2018-02-28
Vanguard Balanced Index Inv 20700 0.07% -- -- 2018-02-28
Putnam Small Cap Growth A 21556 0.09% 15661 265.67% 2017-12-31
iShares Core S&P Total US Stock Mkt 7553 0.04% 26 0.35% 2018-01-30
BNY Mellon EB DL Mkt Completion 15167 0.06% 1697 12.60% 2017-12-31
DFA Tax-Managed US Small Cap 9732 0.04% -- -- 2017-11-30
AMG Managers Special Equity Service 13785 0.05% -- -- 2017-11-30
BNY Mellon Market Completion Fund UC1 13470 0.05% 12862 2115.46% 2017-09-30
CREF Stock R1 52840 0.27% -- -- 2016-12-31
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 31248 0.16% 229 0.74% 2016-12-31
The Vanguard Russell 2000 Growth Index 19903 0.10% -- -- 2016-12-31
JNL/Mellon Capital Healthcare Sector B 14088 0.07% -- -- 2016-09-30
Schwab Small Cap Index 18048 0.09% -- -- 2016-12-31
AXA 2000 Managed Volatility K 15689 0.08% -- -- 2016-11-30
BlackRock Russell 2000 16425 0.08% 912 5.88% 2016-12-31
EQ/Small Company Index IA 13800 0.07% -- -- 2016-11-30
TIAA-CREF Small-Cap Blend Idx Inst 14056 0.07% -- -- 2016-12-31
Fidelity® Advisor Small Cap Opps Fund 585269 3.60% -173700 -22.90% 2015-07-31
Franklin Biotechnology Discovery 503646 3.10% -- -- 2015-07-31
Fidelity Advisor® Health Care Fund 274000 1.40% -- -- 2015-09-30
iShares Russell 2000 (AU) 183792 1.10% -117 -0.10% 2015-11-18
DWS Biotech 180000 0.80% -- -- 2015-09-30
Fidelity® Contrafund® Fund 172900 0.90% 172900 -- 2015-09-30
Fidelity® Small Cap Growth Fund 169700 1.00% -- -- 2015-07-31
Fidelity® Stock Selector Small Cap Fund 158506 1.00% -42900 -21.30% 2015-07-31
Fidelity® Blue Chip Growth Fund 148440 0.80% 148440 -- 2015-09-30
Fidelity® Select Health Care Portfolio 900000 4.70% -- -- 2015-09-30
Fidelity VIP Health Care Portfolio 120000 0.60% -- -- 2015-09-30

Faheem Hasnain Founder of Gossamer Bio, Inc., Faheem Hasnain is a businessperson who has been at the head of 10 different companies and currently occupies the position of Non-Executive Chairman for Gossamer Bio, Inc., Chairman for Mirati Therapeutics, Inc., Chairman at SENT�0�1‰, Inc. (California) and Chairman of Tocagen, Inc. He is also on the board of Kura Oncology, Inc. and Member-Overseers Board at The Scripps Research Institute. In his past career he was President, Chief Executive Officer & Director at PDL BioPharma, Inc., Executive Vice President of Biogen, Inc. and EVP-Oncology & Rheumatology Strategic Business Unit at Biogen Idec, Inc. (North Carolina) (a subsidiary of Biogen, Inc.), President-Oncology Therapeutics Network at Bristol-Myers Squibb Co., Vice President-Global eBusiness at GlaxoSmithKline Plc, Chairman at Vital Therapies, Inc., Chairman at Ambit Biosciences Corp., President, Chief Executive Officer & Director at Receptos LLC, President, Chief Executive Officer & Director at Abbott Biotherapeutics Corp. and President for Oncology Therapeutics Network Corp. Mr. Hasnain received an undergraduate degree from the University of Windsor.
Jamie A. Donadio Jamie A. Donadio is Chief Financial Officer & Senior Vice President at Mirati Therapeutics, Inc. In the past Mr. Donadio held the position of Senior Director-Finance at Amylin Pharmaceuticals, Inc. and Senior Accountant at Novatel Wireless, Inc. He received an undergraduate degree from Babson College.
Bruce Leonard Andrews Carter Bruce Leonard Andrews Carter is a businessperson who has been at the head of 7 different companies. Presently, he holds the position of Non-Executive Chairman at Enanta Pharmaceuticals, Inc. He is also on the board of Dr. Reddy's Laboratories Ltd., Mirati Therapeutics, Inc., Aurigene Discovery Technologies Ltd. and Navigating Cancer, Inc. and Chairman of Global Alliance for TB Drug Development and Professor at the University of Washington. In his past career Bruce Leonard Andrews Carter was Chairman for Xencor, Inc., Chairman for Infectious Disease Research Institute, Executive Chairman of Infectious Disease Research Institute, Chief Scientific Officer & Executive VP at Novo Nordisk A, Chairman at ZymoGenetics, Inc., Executive Chairman at Immune Design Corp., Head-Molecular Genetics at G.D. Searle & Co., Inc. and Director at McAdams Wright Ragen, Inc. He received an undergraduate degree from The University of Nottingham and a doctorate from Queen Elizabeth College.
Henry J. Fuchs Henry J. Fuchs holds the position of President-Worldwide Research & Development at BioMarin Pharmaceutical, Inc. He is also on the board of Genomic Health, Inc. and Mirati Therapeutics, Inc. In the past Dr. Fuchs occupied the position of Independent Director at Ardea Biosciences, Inc., Chief Medical Officer & Executive Vice President at Onyx Pharmaceuticals, Inc. and Principal at Genentech, Inc. Henry J. Fuchs received a doctorate from George Washington University and an undergraduate degree from Harvard University.
Michael G. Grey Founder of Mirum Pharmaceuticals, Inc., Lumena Pharmaceuticals, Inc. and Reneo Pharmaceuticals, Inc., Michael G. Grey is an entrepreneur and businessperson who has been the head of 14 different companies and currently is Executive Chairman of Amplyx Pharmaceuticals, Inc., Executive Chairman for Reneo Pharmaceuticals, Inc., Executive Chairman of Spruce Biosciences, Inc., Executive Chairman for Mirum Pharmaceuticals, Inc. and Venture partner at Pappas Capital LLC. Michael G. Grey is also on the board of 7 other companies. In the past Mr. Grey held the position of President & Chief Operating Officer for Ansan, Inc., Independent Director at Ziarco Pharma Ltd., Executive Chairman for Ziarco Group Ltd., Non-Executive Chairman for IDM Pharma, Inc., President, Chief Executive Officer & Director at Lumena Pharmaceuticals, Inc., President, Chief Executive Officer & Director at Trega Biosciences, Inc., President & Chief Executive Officer at SGX Pharmaceuticals, Inc., President & Chief Operating Officer of Ansan Pharmaceuticals, Inc., President of Biochem Therapeutic, Inc., President & Chief Executive Officer for Auspex Pharmaceuticals, Inc., Vice President-Corporate Development of Glaxo, Inc. and Vice President-Corporate Development of Glaxo Holdings Plc. He received an undergraduate degree from The University of Nottingham.
Julie Michele Cherrington Dr. Julie M. Cherrington is a President, Chief Executive Officer & Director at Arch Oncology, Inc., a Member at American Diabetes Association, a Member at American Society of Clinical Oncology and a Member at American Society of Hematology. She is on the Board of Directors at QUE Oncology, Inc., Mirati Therapeutics, Inc. and Arch Oncology, Inc. Dr. Cherrington was previously employed as a President, Chief Executive Officer & Director by Pathway Therapeutics Ltd., a President, Chief Executive Officer & Director by Pathway Therapeutics, Inc., an Independent Non-Executive Director by Progen Pharmaceuticals Ltd., an Independent Non-Executive Director by ChemGenex Pharmaceuticals Pty Ltd., a President by Phenomix Australia Pty Ltd., a President by Phenomix Corp., a VP-Preclinical Research & Exploratory Development by SUGEN, Inc., a Member by American Association for Cancer Research, a Virology Director by Gilead Sciences, Inc., and a Chairman by Xenome Ltd. She received her undergraduate degree from the University of California, Davis, a graduate degree from the University of California, Davis and a doctorate degree from the University of Minnesota.
Craig A. Johnson Craig A. Johnson is on the board of Heron Therapeutics, Inc., La Jolla Pharmaceutical Co., Mirati Therapeutics, Inc. and Odonate Therapeutics, Inc. In the past Mr. Johnson occupied the position of Chief Financial Officer, Secretary & Senior VP at NovaDel Pharma, Inc., Chief Financial Officer for PURE Bioscience, Inc., President for Philip Morris USA, Inc., Chief Financial Officer & Senior VP-Operations at MitoKor, Inc., Chief Financial Officer & Vice President of TorreyPines Therapeutics, Inc., Chief Financial Officer & Vice President of TPTX, Inc. and Vice President of Horizon Pharmaceutical LLC. He received an undergraduate degree from The University of Michigan-Dearborn.
Christopher C. LeMasters Founder of Cabrellis Pharmaceuticals Corp., Adastra Pharmaceuticals, Inc., Aarden Pharmaceuticals, Inc. and Hoosier Oncology Group, Inc., Christopher C. LeMasters is an entrepreneur is on the board of Promosome LLC (former Chief Executive Officer & Director) and Hoosier Oncology Group, Inc. and Chief Business Officer & Executive Vice President at Mirati Therapeutics, Inc. Mr. LeMasters previously was Chief Business Officer at Adastra Pharmaceuticals, Inc., Auditor of Owens Corning, Principal at Eli Lilly & Co., Vice President-Business Development of Conforma Therapeutics Corp., Chief Business Officer for Cabrellis Pharmaceuticals Corp., Consultant at Coopers & Lybrand Consulting, Inc. and Director at Aarden Pharmaceuticals, Inc. Mr. LeMasters received an undergraduate degree from Indiana University and an MBA from The University of Chicago.
Michael G. Grey Founder of Mirum Pharmaceuticals, Inc., Lumena Pharmaceuticals, Inc. and Reneo Pharmaceuticals, Inc., Michael G. Grey is an entrepreneur and businessperson who has been the head of 14 different companies and currently is Executive Chairman of Amplyx Pharmaceuticals, Inc., Executive Chairman for Reneo Pharmaceuticals, Inc., Executive Chairman of Spruce Biosciences, Inc., Executive Chairman for Mirum Pharmaceuticals, Inc. and Venture partner at Pappas Capital LLC. Michael G. Grey is also on the board of 7 other companies. In the past Mr. Grey held the position of President & Chief Operating Officer for Ansan, Inc., Independent Director at Ziarco Pharma Ltd., Executive Chairman for Ziarco Group Ltd., Non-Executive Chairman for IDM Pharma, Inc., President, Chief Executive Officer & Director at Lumena Pharmaceuticals, Inc., President, Chief Executive Officer & Director at Trega Biosciences, Inc., President & Chief Executive Officer at SGX Pharmaceuticals, Inc., President & Chief Operating Officer of Ansan Pharmaceuticals, Inc., President of Biochem Therapeutic, Inc., President & Chief Executive Officer for Auspex Pharmaceuticals, Inc., Vice President-Corporate Development of Glaxo, Inc. and Vice President-Corporate Development of Glaxo Holdings Plc. He received an undergraduate degree from The University of Nottingham.
Reed Vickerman Mr. Reed Vickerman is Chief Operating Officer at Everyone Counts, Inc. Mr. Vickerman was previously employed as Chairman by San Diego Data Processing Corp., Vice President-Corporate Operations by Amylin Pharmaceuticals, Inc., Chief Operating & Financial Officer by San Diego Museum of Art, a Director-Information Technology by Advanced Tissue Sciences, Inc., a Principal by PricewaterhouseCoopers LLP, a Principal by Hewlett-Packard Co., Senior Director-Information Technology by Dura Pharmaceuticals, Inc., and Vice President-Information Technology & Facilities by Copper Mountain Networks, Inc. He received his undergraduate degree from Carnegie Mellon University.
Perry C. Johnston Currently, Perry C. Johnston holds the position of Secretary, VP, Chief Legal & Compliance Officer at Mirati Therapeutics, Inc. He previously occupied the position of Principal at Jostens, Inc., Secretary, Vice President & General Counsel at Advanced BioEnergy LLC, Secretary, Vice President & General Counsel at Nevada Cancer Institute, Senior Legal Counsel at Medtronic, Inc., Senior Director-Legal at Amylin Pharmaceuticals, Inc., Vice President-Legal & Compliance at Cardionet LLC and Vice President-Legal, Regulatory & Compliance at Aperio Technologies, Inc. Perry C. Johnston received a graduate degree from The University of Minnesota Law School and an undergraduate degree from The Curtis L. Carlson School of Management.
Neil A. Reisman Neil A. Reisman is a businessperson who has been the head of 6 different companies. Mr. Reisman occupies the position of Chairman of Nucleus Biologics, President, CEO, Manager & Assistant Secretary at Ficus Investments LLC, President & Director at RPFG Holdings, Inc., President for Lumenta Products LLC, President & Director at Tavistock Capital Group, Inc. and Managing Director & Director at Tavistock Group, Inc., President & Director at RoundPoint Financial Group, Inc. and Vice President & Assistant Secretary at RoundPoint Mortgage Co. (both are subsidiaries of Tavistock Group, Inc.). He is also on the board of Australian Agricultural Co. Ltd. and Mirati Therapeutics, Inc. and Manager of Baycorp Grec LLC, Vice President & Assistant Secretary at RoundPoint Mortgage Co., Manager at Biloxi Capital LLC, Manager for Tavistock Genome LLC and Manager of US Property & Financial Services LLC. In his past career he occupied the position of Chief Operating Officer for Kalypsys, Inc., Principal at Arthur Andersen LLP, CFO, Chief Operating Officer & General Counsel at CovX Research LLC, Principal at Borg Warner Security Corp., Principal at Amoco Corp. and Principal at Comdisco, Inc. Neil A. Reisman received an undergraduate degree from the University of Illinois and a graduate degree from the University of Pennsylvania.
Claire S. Padgett Claire S. Padgett is Senior Vice President-Clinical Operations at Mirati Therapeutics, Inc. Dr. Padgett previously was Vice President-Clinical Operations at Cylene Pharmaceuticals, Inc., Vice President-Clinical Operations at Oncolytics Biotech, Inc., Vice President-Clinical Operations at Mast Therapeutics, Inc. and Executive Director-Clinical Operations at Conforma Therapeutics Corp. Dr. Padgett received a graduate degree and an MBA from Seton Hall University, an undergraduate degree from Rutgers State University of New Jersey and a doctorate from Capella University, Inc.
Henry J. Fuchs Henry J. Fuchs holds the position of President-Worldwide Research & Development at BioMarin Pharmaceutical, Inc. He is also on the board of Genomic Health, Inc. and Mirati Therapeutics, Inc. In the past Dr. Fuchs occupied the position of Independent Director at Ardea Biosciences, Inc., Chief Medical Officer & Executive Vice President at Onyx Pharmaceuticals, Inc. and Principal at Genentech, Inc. Henry J. Fuchs received a doctorate from George Washington University and an undergraduate degree from Harvard University.
Charles M. Baum Currently, Charles M. Baum holds the position of President, Chief Executive Officer & Director at Mirati Therapeutics, Inc. Dr. Baum is also on the board of Immunomedics, Inc. and Array BioPharma, Inc. In the past he was Senior VP & Head-Clinical Research at Pfizer Inc. Charles M. Baum received a doctorate from Washington University School of Medicine.
Isan Chen Isan Chen occupies the position of EVP, Chief Medical & Development Officer at Mirati Therapeutics, Inc. In the past he occupied the position of Assistant Professor at Anderson Cancer Center, Vice President-Tumor Strategy at Pfizer Inc. and Chief Medical Officer of Aragon Pharmaceuticals, Inc.
James G. Christensen James G. Christensen holds the position of Chief Scientific Officer & Executive VP at Mirati Therapeutics, Inc. He previously held the position of Senior Director-Oncology Precision Medicine at Pfizer Inc. Dr. Christensen received a doctorate from North Carolina State University.
Jessica M. Corson Jessica M. Corson is Senior Director-Business Development at Mirati Therapeutics, Inc.
Temre Johnson Temre Johnson holds the position of Director-Investor Relations & Communications at Mirati Therapeutics, Inc.
Aaron I. Davis Aaron I. Davis founded Boxer Capital LLC. Presently, he is Executive Chairman at CiVi Biopharma, Inc. and Chief Executive Officer of Boxer Capital LLC. Mr. Davis is also on the board of Mirati Therapeutics, Inc., Sojournix, Inc. and Odonate Therapeutics, Inc. Mr. Davis previously held the position of Principal at UBS Securities LLC and Vice President of Tavistock Life Sciences Co. Aaron I. Davis received a graduate degree from Columbia University and an undergraduate degree from Emory University.
Maya Martinez-Davis Maya Martinez-Davis is on the board of Mirati Therapeutics, Inc. and President-Biopharma Latin America at Merck KGaA. She received an undergraduate degree from St. Louis University and a graduate degree from Instituto de Empresa SL.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐